Meeting
2016 ASCO Annual Meeting
Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.
Authors
Marc Peeters
Antwerp University Hospital, Edegem, Belgium
Marc Peeters , Tae Won Kim , Jin Li , Stefano Cascinu , Paul Ruff , Attili Venkatasatya Suresh , Anne Thomas , Sergei Tjulandin , Xuesong Guan , Timothy Jay Price
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01001377
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3538)
DOI
10.1200/JCO.2016.34.15_suppl.3538
Abstract #
3538
Poster Bd #
235
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.
First Author: Marc Peeters
Poster
2018 Gastrointestinal Cancers Symposium
Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G.
First Author: Hiroya Taniguchi
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.
First Author: Kaori Hayashi
Poster
2015 ASCO Annual Meeting
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial.
First Author: Stefan Kasper